In March BIOCAD biotechnology company was granted access to supply highly demanded medicine - rituximab biosimilar to Vietnam for a second time. It means that BIOCAD partners will continue to supply local hospitals with the Russian product and patients will get access to affordable and effective treatment in Vietnam.
BIOCAD is going to receive permanent registration certificate for the medicine in the end of the 3rd - beginning of the 4thquarter 2017. It will allow the company to export the product from Russia without any limitations.
International expansion is one of BIOCAD’s strategic goals and entering a new market is always an achievement. Vietnam is among the company’s priority markets, because it is one of the fastest-growing economies in Southeast Asia.
Today rituximab biosimilar developed and produced by BIOCAD has already entered international markets including Southeast Asia, Middle East, and CIS countries. By the end of 2017 the medicine should appear in the markets of India and Sri-Lanka.